US Patent No. 7,727,564
|
|
CLAIMS
|
1. A method of inhibiting cyclooxygenase enzyme activity in a mammal, the method comprising administering to the mammal an effective amount of a dietary supplement comprising freeze-dried Acai fruit pulp composition, wherein the composition comprises: (a) a total anthocyanin concentration greater than about 1 milligram per gram total weight; (b) an ORAC.sub.FL value greater than about 350 micromole TE per gram total weight; and (c) a residual water content less than about 3 weight percent of the total weight; or an effective amount of a freeze-dried Acai fruit pulp composition, wherein the composition comprises a cyclooxygenase inhibition value greater than about 15 Aspirin.RTM. mg equivalent per gram total weight and a residual water content less than about 3 weight percent of the total weight.
2. The method of claim 1, wherein the composition comprises a pharmaceutically acceptable carrier. 3. The method of claim 1, wherein the composition is administered by a route of administration selected from the group consisting of: oral, intravenous, intraperitoneal, subcutaneous, intramuscular, intraarticular, intraarterial, intracerebral, intracerebellar, intrabronchial, intrathecal, topical, and aerosol route. 4. A method of treating a disease or an injury associated with increased cyclooxygenase enzyme activity in a mammal, the method comprising administering to the mammal an effective amount of a dietary supplement comprising a freeze-dried Acai fruit pulp composition, wherein the composition comprises: (a) a total anthocyanin concentration greater than about 1 milligram per gram total weight; (b) an ORAC.sub.FL value greater than about 350 micromole TE per gram total weight; and (c) a residual water content less than about 3 weight percent of the total weight; or an effective amount of a freeze-dried Acai fruit pulp composition, wherein the composition comprises a cyclooxygenase inhibition value greater than about 15 Aspirin.RTM. mg equivalent per gram total weight and a residual water content less than about 3 weight percent of the total weight. 5. The method of claim 4, wherein the composition further comprises a pharmaceutically acceptable carrier. 6. The method of claim 4, wherein the composition is administered by a route of administration selected from the group consisting of: oral, intravenous, intraperitoneal, subcutaneous, intramuscular, intraarticular, intraarterial, intracerebral, intracerebellar, intrabronchial, intrathecal, topical, and aerosol route. 7. The method of claim 4, wherein the disease or injury is selected from the group consisting of: cancer, colon cancer, breast cancer, inflammatory bowel disease, Crohn's disease, vascular disease, arthritis, ulcer, acute respiratory distress syndrome, ischemia-reperfusion injury, neurodegenerative disorders, autism, Parkinson's Disease, Alzheimer's Disease, gastrointestinal disease, tissue injury induced by inflammation, and tissue injury induced by an environmental toxin. |